{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T04:23:43Z","timestamp":1728447823882},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T00:00:00Z","timestamp":1380758400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T00:00:00Z","timestamp":1380758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Not all breast cancer patients respond to tamoxifen treatment, possibly due to genetic predisposition. As tamoxifen-induced reductions in percent mammographic density (PMD) have been linked to the risk and prognosis of breast cancer, we conducted a candidate gene study to investigate the association between germline <jats:italic>CYP2D6<\/jats:italic> polymorphisms and PMD change.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>Baseline and follow-up mammograms were retrieved for 278 tamoxifen-treated subjects with <jats:italic>CYP2D6<\/jats:italic> metabolizer status (extensive (EM), heterozygous extensive\/intermediate (hetEM\/IM) or poor metabolizer (PM)). Logistic regression analyses were conducted comparing subjects who experienced &gt;10% reduction in PMD to those who experienced \u226410% reduction or increase.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>After multivariate adjustment, PMD change was found to be significantly associated with the degree of <jats:italic>CYP2D6<\/jats:italic> enzyme functionality (Ptrend\u2009=\u20090.021). Compared with EM, hetEM\/IM and PM were 72% (95% confidence interval (CI): 0.10 to 0.79) and 71% (0.03 to 2.62) less likely to experience a &gt;10% reduction, respectively.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Tamoxifen-induced change in PMD appears to have a genetic component.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/bcr3495","type":"journal-article","created":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T03:01:17Z","timestamp":1380769277000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Association of CYP2D6metabolizer status with mammographic density change in response to tamoxifen treatment"],"prefix":"10.1186","volume":"15","author":[{"given":"Jingmei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamila","family":"Czene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiltrud","family":"Brauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Schroth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Saladores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Humphreys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,3]]},"reference":[{"key":"3577_CR1","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/jnci\/djk049","volume":"99","author":"J Cuzick","year":"2007","unstructured":"Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A: Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007, 99: 272-282. 10.1093\/jnci\/djk049.","journal-title":"J Natl Cancer Inst"},{"key":"3577_CR2","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011, 378: 771-784.","journal-title":"Lancet"},{"key":"3577_CR3","doi-asserted-by":"publisher","first-page":"R102","DOI":"10.1186\/bcr3221","volume":"14","author":"J Kim","year":"2012","unstructured":"Kim J, Han W, Moon HG, Ahn SK, Shin HC, You JM, Han SW, Im SA, Kim TY, Koo HR, Chang JM, Cho N, Moon WK, Noh DY: Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res. 2012, 14: R102-10.1186\/bcr3221.","journal-title":"Breast Cancer Res"},{"key":"3577_CR4","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/jnci\/djr079","volume":"103","author":"J Cuzick","year":"2011","unstructured":"Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RM: Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case\u2013control study. J Natl Cancer Inst. 2011, 103: 744-752. 10.1093\/jnci\/djr079.","journal-title":"J Natl Cancer Inst"},{"key":"3577_CR5","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1200\/JCO.2012.44.5015","volume":"31","author":"J Li","year":"2013","unstructured":"Li J, Humphreys K, Eriksson L, Edgren G, Czene K, Hall P: Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. J Clin Oncol. 2013, 31: 2249-2256. 10.1200\/JCO.2012.44.5015.","journal-title":"J Clin Oncol"},{"key":"3577_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/sj.clpt.6100367","volume":"83","author":"MP Goetz","year":"2008","unstructured":"Goetz MP, Kamal A, Ames MM: Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther. 2008, 83: 160-166. 10.1038\/sj.clpt.6100367.","journal-title":"Clin Pharmacol Ther"},{"key":"3577_CR7","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1001\/jama.2009.1420","volume":"302","author":"W Schroth","year":"2009","unstructured":"Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Bol\u00e4nder J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009, 302: 1429-1436. 10.1001\/jama.2009.1420.","journal-title":"JAMA"},{"key":"3577_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/(SICI)1097-0215(19980330)76:1<29::AID-IJC6>3.0.CO;2-#","volume":"76","author":"C Magnusson","year":"1998","unstructured":"Magnusson C, Baron J, Persson I, Wolk A, Bergstrom R, Trichopoulos D, Adami HO: Body size in different periods of life and breast cancer risk in post-menopausal women. Int J Cancer. 1998, 76: 29-34. 10.1002\/(SICI)1097-0215(19980330)76:1<29::AID-IJC6>3.0.CO;2-#.","journal-title":"Int J Cancer"},{"key":"3577_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6","volume":"81","author":"C Magnusson","year":"1999","unstructured":"Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I: Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer. 1999, 81: 339-344. 10.1002\/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6.","journal-title":"Int J Cancer"},{"key":"3577_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/(SICI)1097-0215(19990118)80:2<231::AID-IJC11>3.0.CO;2-R","volume":"80","author":"CM Magnusson","year":"1999","unstructured":"Magnusson CM, Persson IR, Baron JA, Ekbom A, Bergstrom R, Adami HO: The role of reproductive factors and use of oral contraceptives in the aetiology of breast cancer in women aged 50 to 74 years. Int J Cancer. 1999, 80: 231-236. 10.1002\/(SICI)1097-0215(19990118)80:2<231::AID-IJC11>3.0.CO;2-R.","journal-title":"Int J Cancer"},{"key":"3577_CR11","doi-asserted-by":"publisher","first-page":"R437","DOI":"10.1186\/bcr811","volume":"6","author":"S Wedren","year":"2004","unstructured":"Wedren S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvanen AC, Kindmark A, Landegren U, Fermer ML, Stiger F, Persson I, Baron J, Weiderpass E: Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res. 2004, 6: R437-R449. 10.1186\/bcr811.","journal-title":"Breast Cancer Res"},{"key":"3577_CR12","first-page":"1301","volume":"145","author":"J Isola","year":"1994","unstructured":"Isola J, DeVries S, Chu L, Ghazvini S, Waldman F: Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol. 1994, 145: 1301-1308.","journal-title":"Am J Pathol"},{"key":"3577_CR13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","volume":"24","author":"JF Ludvigsson","year":"2009","unstructured":"Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A: The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009, 24: 659-667. 10.1007\/s10654-009-9350-y.","journal-title":"Eur J Epidemiol"},{"key":"3577_CR14","doi-asserted-by":"publisher","first-page":"R114","DOI":"10.1186\/bcr3238","volume":"14","author":"J Li","year":"2012","unstructured":"Li J, Szekely L, Eriksson L, Heddson B, Sundbom A, Czene K, Hall P, Humphreys K: High-throughput mammographic-density measurement: a tool for risk prediction of breast cancer. Breast Cancer Res. 2012, 14: R114-10.1186\/bcr3238.","journal-title":"Breast Cancer Res"},{"key":"3577_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1148\/radiol.09091090","volume":"255","author":"JH Chen","year":"2010","unstructured":"Chen JH, Nie K, Bahri S, Hsu CC, Hsu FT, Shih HN, Lin M, Nalcioglu O, Su MY: Decrease in breast density in the contralateral normal breast of patients receiving neoadjuvant chemotherapy: MR imaging evaluation. Radiology. 2010, 255: 44-52. 10.1148\/radiol.09091090.","journal-title":"Radiology"},{"key":"3577_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1259\/0007-1285-59-700-337","volume":"59","author":"JH Buckley","year":"1986","unstructured":"Buckley JH, Roebuck EJ: Mammographic changes following radiotherapy. Br J Radiol. 1986, 59: 337-344. 10.1259\/0007-1285-59-700-337.","journal-title":"Br J Radiol"},{"key":"3577_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.acra.2009.01.021","volume":"16","author":"CM Kuzmiak","year":"2009","unstructured":"Kuzmiak CM, Zeng D, Cole E, Pisano ED: Mammographic findings of partial breast irradiation. Acad Radiol. 2009, 16: 819-825. 10.1016\/j.acra.2009.01.021.","journal-title":"Acad Radiol"},{"key":"3577_CR18","volume-title":"R: A language and environment for statistical computing","author":"R Development Core Team","year":"2008","unstructured":"R Development Core Team: R: A language and environment for statistical computing. 2008, Vienna, Austria: R Foundation for Statistical Computing"},{"key":"3577_CR19","first-page":"3706","volume":"60","author":"RJ Osborne","year":"2000","unstructured":"Osborne RJ, Hamshere MG: A genome-wide map showing common regions of loss of heterozygosity\/allelic imbalance in breast cancer. Cancer Res. 2000, 60: 3706-3712.","journal-title":"Cancer Res"},{"key":"3577_CR20","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1093\/jnci\/djs304","volume":"104","author":"Y Nakamura","year":"2012","unstructured":"Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA: Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1\u201398 trial. J Natl Cancer Inst. 2012, 104: 1266-1268. 10.1093\/jnci\/djs313.","journal-title":"J Natl Cancer Inst"},{"key":"3577_CR21","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1093\/aje\/kwn063","volume":"167","author":"LE Kelemen","year":"2008","unstructured":"Kelemen LE, Pankratz VS, Sellers TA, Brandt KR, Wang A, Janney C, Fredericksen ZS, Cerhan JR, Vachon CM: Age-specific trends in mammographic density: the Minnesota breast cancer family study. Am J Epidemiol. 2008, 167: 1027-1036. 10.1093\/aje\/kwn063.","journal-title":"Am J Epidemiol"},{"key":"3577_CR22","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1158\/1055-9965.EPI-05-0798","volume":"15","author":"G Maskarinec","year":"2006","unstructured":"Maskarinec G, Pagano I, Lurie G, Kolonel LN: A longitudinal investigation of mammographic density: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2006, 15: 732-739. 10.1158\/1055-9965.EPI-05-0798.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"3577_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/ng.760","volume":"43","author":"S Lindstrom","year":"2011","unstructured":"Lindstrom S, Vachon CM, Li J, Varghese J, Thompson D, Warren R, Brown J, Leyland J, Audley T, Wareham NJ, Loos RJ, Paterson AD, Rommens J, Waggott D, Martin LJ, Scott CG, Pankratz VS, Hankinson SE, Hazra A, Hunter DJ, Hopper JL, Southey MC, Chanock SJ, Silva Idos S, Liu J, Eriksson L, Couch FJ, Stone J, Apicella C, Czene K, et al: Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nat Genet. 2011, 43: 185-187. 10.1038\/ng.760.","journal-title":"Nat Genet"},{"key":"3577_CR24","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/jnci\/djs327","volume":"104","author":"GL Gierach","year":"2012","unstructured":"Gierach GL, Ichikawa L, Kerlikowske K, Brinton LA, Farhat GN, Vacek PM, Weaver DL, Schairer C, Taplin SH, Sherman ME: Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. J Natl Cancer Inst. 2012, 104: 1218-1227. 10.1093\/jnci\/djs327.","journal-title":"J Natl Cancer Inst"},{"key":"3577_CR25","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1200\/JCO.2010.31.4427","volume":"29","author":"WJ Irvin Jr","year":"2011","unstructured":"Irvin WJ, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST, Raab RE, Corso SW, Peppercorn JM, Anderson SM, Friedman KJ, Ogburn ET, Desta Z, Flockhart DA, McLeod HL, Evans JP, Carey LA: Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol. 2011, 29: 3232-3239. 10.1200\/JCO.2010.31.4427.","journal-title":"J Clin Oncol"},{"key":"3577_CR26","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/clpt.2011.153","volume":"90","author":"MF Barginear","year":"2011","unstructured":"Barginear MF, Jaremko M, Peter I, Yu C, Kasai Y, Kemeny M, Raptis G, Desnick RJ: Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther. 2011, 90: 605-611. 10.1038\/clpt.2011.153.","journal-title":"Clin Pharmacol Ther"},{"key":"3577_CR27","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/jnci\/djs126","volume":"104","author":"JM Rae","year":"2012","unstructured":"Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012, 104: 452-460. 10.1093\/jnci\/djs126.","journal-title":"J Natl Cancer Inst"},{"key":"3577_CR28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/jnci\/djs125","volume":"104","author":"MM Regan","year":"2012","unstructured":"Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thurlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1\u201398 Trial. J Natl Cancer Inst. 2012, 104: 441-451. 10.1093\/jnci\/djs125.","journal-title":"J Natl Cancer Inst"},{"key":"3577_CR29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1200\/JCO.2012.44.6625","volume":"31","author":"H Brauch","year":"2013","unstructured":"Brauch H, Schroth W, Goetz MP, Murdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M: Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol. 2013, 31: 176-180. 10.1200\/JCO.2012.44.6625.","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr3495.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/bcr3495\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr3495.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:39:04Z","timestamp":1728383944000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/bcr3495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,3]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,10]]}},"alternative-id":["3577"],"URL":"https:\/\/doi.org\/10.1186\/bcr3495","relation":{},"ISSN":["1465-542X"],"issn-type":[{"type":"electronic","value":"1465-542X"}],"subject":[],"published":{"date-parts":[[2013,10,3]]},"assertion":[{"value":"26 June 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R93"}}